# Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

> **NCT01413906** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 12 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** BMS-833923 (XL139)

## Key facts

- **NCT ID:** NCT01413906
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01413906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01413906, "Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01413906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*